News

Zacks Investment Research on MSN19h
Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights
In the latest close session, Moderna (MRNA) was down 1.87% at $33.64. This move lagged the S&P 500's daily loss of 0.33%. Meanwhile, the Dow lost 0.63%, and the Nasdaq, a tech-heavy index, lost 0.22%.
StockStory.org on MSN2d
Why Moderna (MRNA) Stock Is Up Today
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 3.8% in the morning session after the U.S. Food ...
Moderna (MRNA) Jumps 8.8% on COVID-19 Support from Medical Organizations
Moderna, Inc. (NASDAQ:MRNA) is one of These 10 Stocks Are Making Big Moves. Moderna Inc. jumped by 8.83 percent on Tuesday to ...
Moderna says mRNA flu vaccine sailed through trial, beating standard shot
Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...
STAT12dOpinion
The U.S. must invest in mRNA vaccines against pandemic influenza viruses now
If we don’t invest in technologies like mRNA vaccines for pandemic influenza now, once a virus starts going human-to-human, ...
BioSpace12d
Moderna’s Promised mRNA Flu Vaccine Bests Current Standard Shot
In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...
PMLive4d
Moderna shares positive phase 3 results for mRNA flu vaccine candidate
“ [These] strong phase 3 efficacy results are a significant milestone in our effort to reduce the burden of influenza in ...
Moderna, Inc.: Moderna to Report Second Quarter 2025 Financial Results on Friday, August 1, 2025
CAMBRIDGE, MA / ACCESS Newswire / July 11, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, August 1, 2025 to report i ...